Moderna (MRNA) Rises 9% After Phase 3 Melanoma Study Symposium Slot
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowModerna (MRNA) shares surged 9% to $168 after its Phase 3 melanoma vaccine study was selected for the Presidential Symposium slot at the European Society for Medical Oncology congress on October 24. Meanwhile, Merck (MRK) gained 1% and BioNTech (BNTX) increased 2%. The selection highlights the significance of the study, although no new efficacy data was released. This offers a signal to investors that the research may lead to practice-changing developments in cancer treatment, impacting Moderna's evaluation and future opportunities.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Merck & Co. Inc. (MRK)
Merck is a global pharmaceutical company best known for its oncology, vaccine, and animal-health franchises.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier MRK news
- Moderna (MRNA) and Merck (MRK) Announce Cancer Vaccine Breakthrough
- Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
- Moderna (MRNA) Cancer Vaccine Shows 150% Stock Surge Potential
- Moderna (MRNA) Shares Double on Melanoma Vaccine Trial Success
- Moderna (MRNA) cancer vaccine trial shows positive early results
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
